Avastin (bevacizumab) / Roche - LARVOL DELTA

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov) - P2 | N=88 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Dec 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Psoriatic Arthritis • Solid Tumor • IL2

ENGOT-ov57: Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer (clinicaltrials.gov) - P3 | N=970 | Recruiting | Sponsor: AGO Study Group | Trial completion date: Sep 2030 ➔ Dec 2031 | Trial primary completion date: Feb 2028 ➔ Dec 2028

Trial completion date • Trial primary completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial (clinicaltrials.gov) - P3 | N=252 | Not yet recruiting | Sponsor: NRG Oncology

New P3 trial • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial). (PubMed, BMJ Open) - P2 | "A/B substantially improved objective response rates compared with tyrosine kinase inhibitor sorafenib; however, a majority of patients will still not respond to A/B...Primary endpoints are measured as tumour CD8+ T cell infiltration after 2 cycles of treatment with vancomycin, A/B+INTESTIFIX 001 in comparison to vancomycin-placebo, A/B+INTESTIFIX 001-placebo and safety of the therapeutic combination in advanced HCC...The outcome of the study will be disseminated via peer-reviewed publications and at international conferences. NCT05690048."

Clinical protocol • Journal • P2 data • Biliary Cancer • Fibrosis • Gastroenterology • Hepatocellular Cancer • Hepatology • Immunology • Liver Cancer • Liver Cirrhosis • Melanoma • Oncology • Solid Tumor • CD8 • PD-L1

BFAST: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - P2/3 | N=1000 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Aug 2028 ➔ Oct 2026 | Trial primary completion date: Aug 2028 ➔ Oct 2026

Trial completion date • Trial primary completion date • Tumor mutational burden • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BRAF

BELLA: A Phase 2 Study of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (ESMO 2025) - No abstract available

Clinical • P2 data • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

TroFuse-022/ENGOT-ov84/GOG-3103 Part 1: A Phase 3 Study of Sacituzumab Tirumotecan (Sac-TMT) ± Bevacizumab (Bev) Maintenance Therapy vs Standard of Care (SoC) After Second-Line (2L) Platinum-Based Doublet Chemotherapy (Chemo) for Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) (ESMO 2025) - No abstract available

Clinical • P3 data • Platinum sensitive • Oncology • Ovarian Cancer • Solid Tumor

Nanoliposomal irinotecan in combination with oxalipalatin and bevacizumab versus nanoliposomal irinotecan with 5-fluorouracil/leucovorin in metastatic pancreatic cancer after previous treatment-naive therapy: a multicenter, randomised, open-label, phase I/II trial (ESMO 2025) - No abstract available

Clinical • Combination therapy • Metastases • P1/2 data • Oncology • Pancreatic Cancer • Solid Tumor

A Real-world Study of Sintilimab plus Bevacizumab plus Platinum Combined with Taxane or Pemetrexed Chemotherapy as First-line Treatment for Advanced Wild-type Non-Squamous Non-small Cell Lung Cancer (ESMO 2025) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase 1b/2 study of arfolitixorin in combination with 5-fluorouracil (5FU), oxaliplatin, and bevacizumab as first-line therapy for metastatic colorectal cancer (mCRC) (ESMO 2025) - No abstract available

Clinical • Combination therapy • Metastases • P1/2 data • Colorectal Cancer • Oncology • Solid Tumor

FTM-JSNO-03:A phase II study of fecal microbiota transplantation (FMT) plus QL1706 plus Bevacizumab plus XELOX for first-line (1L) treatment of advanced Microsatellite-stable (MSS) type colon cancer with liver metastasis (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor

Fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, Phase II Study (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor

Trifluridine-Tipiracil with or without Bevacizumab: what's the benefit in real world experience for metastatic colorectal cancer? (ESMO 2025) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Colorectal Cancer • Oncology • Solid Tumor

Effectiveness of Paclitaxel and Bevacizumab Rechallenge Therapy in Patients with HER2-Negative Metastatic Breast Cancer [WITHDRAWN] (ESMO 2025) - No abstract available

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A new biomarker predicting response to bevacizumab treatment in serous ovarian cancer: HERC2 gene (ESMO 2025) - No abstract available

Biomarker • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

First-line Serplulimab and Bevacizumab Combined with Nab-Paclitaxel/Gemcitabine Followed by mFOLFOX in Advanced Pancreatic Cancer: A Phase II Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

A phase II, two-cohort study of neoadjuvant chemoimmuotherapy ± bevacizumab followed by concurrent chemoradiotherapy and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086) (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Toripalimab Plus Bevacizumab and Chemoradiotherapy as Treatment in Patients With Advanced Melanoma: The IRAC Phase 2 Nonrandomized Clinical Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Melanoma • Oncology • Solid Tumor

Phase I study of ERY974 + atezolizumab (atezo) + bevacizumab (bev) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC) (ESMO 2025) - No abstract available

Clinical • Metastases • P1 data • Hepatocellular Cancer • Oncology • Solid Tumor

A phase 1 study of MTL-CEBPA, atezolizumab (atezo) and bevacizumab (bev) in advanced hepatocellular carcinoma (HCC) (ESMO 2025) - No abstract available

Metastases • P1 data • Hepatocellular Cancer • Oncology • Solid Tumor • CEBPA

SOLARIS – A phase-II open-label Study of pembrOlizumab and Lenvatinib in patients with Advanced stage hepatocellular carcinoma who are Refractory to atezolizumab and bevacizumab/ IO-baSed therapy (IKF t-037 trial) (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Iparomlimab and tuvonralimab (QL1706) plus bevacizumab and/or chemotherapy in first-line treatment for advanced hepatocellular carcinoma: Updated data from the phase 2 part of DUBHE-H-308 study (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Metastatic burden and number of metastatic sites predicts oncological outcomes in patients with HCC treated by atezolizumab/bevacizumab or sorafenib (ESMO 2025) - No abstract available

Clinical • Metastases • Hepatocellular Cancer • Oncology

Infiltrative HCC Defines a Clinically and Molecularly Distinct Subtype with Poor Clinical Outcomes from Atezolizumab plus Bevacizumab (ESMO 2025) - No abstract available

Clinical • Clinical data • Hepatocellular Cancer • Oncology

HERACLIOR: Survival and healthcare pathway of patients with advanced hepatocellular carcinoma treated with Atezolizumab & bevacizumab in France during 2020- 2023 period (ESMO 2025) - No abstract available

Clinical • Metastases • Hepatocellular Cancer • Oncology • Solid Tumor